$161.10
+3.22%Price chart
Sep 30Oct 5Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29
Key dataOct 29, 2026
Open$160.68
From 52W high−4.46%
Volume2.24M
Market cap$304.26B
P/E (TTM)30.7x
P/S (TTM)5.4x
Div yield1.91%
Key dataOct 29, 2026
Open
$160.68
From 52W high
−4.46%
Volume
2.24M
Market cap
$304.26B
ValuationView details →
P/E (Fwd)
16.5x
EV/EBITDA
15.8x
P/E (TTM)
30.7x
RSI (14)
68.5
MomentumView details →
1D Return
+3.22%
YTD Return
+16.17%
SummaryUpdated Sep 1, 2026
Novartis AG (NYSE:NVS) is a Swiss multinational pharmaceutical corporation founded in 1996 through the merger of Ciba-Geigy and Sandoz. Headquartered in Basel, Switzerland, Novartis has evolved into one of the world's largest pharmaceutical companies, focusing on innovative prescription medicines across multiple therapeutic areas. The company completed a significant strategic transformation in 2023 by spinning off its generics division Sandoz, allowing it to focus entirely on developing and commercializing breakthrough treatments for serious diseases.
Similar companies
Latest newsMore news →
NOVARTIS AG reported third-quarter earnings above estimates, with Kisqali, Kesimpta and Scemblix sales offsetting generic competition, while revenue missed estimates.2d agoNOVARTIS AG reported strong third-quarter income, while Kisqali sales fell short of expectations.3d agoNOVARTIS AG shares rose slightly early Tuesday.3d ago